トラスツズマブ デルクステカン (DS-8201a) と HER2 が少ない転移した乳がんに対する治験責任医師の選択 [DESTINY-Breast04]
抗 HER2 抗体薬物複合体 (ADC) である DS-8201a の第 3 相、多施設、無作為化、非盲検、実薬対照試験、対 HER2 低、切除不能、および/または転移性乳癌被験者に対する医師の選択による治療
This study will compare DS-8201a to physician choice standard treatment.
Participants must have HER2-low breast cancer that has been treated before.
Participants' cancer:
- Cannot be removed by an operation
- Has spread to other parts of the body
調査の概要
状態
条件
詳細な説明
This is a randomized, 2-arm, Phase 3, open-label, multicenter study to compare the safety and efficacy of trastuzumab deruxtecan versus the physician's choice (2:1) in HER2-low, unresectable and/or metastatic breast cancer participants.
The Sponsor proposes to define a new HER2-low population in this trial including tumors with IHC 1+ and IHC 2+/ISH- HER2 expression.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Arizona
-
Chandler、Arizona、アメリカ、85224
- Ironwood Cancer & Research Centers - Chandler II
-
Gilbert、Arizona、アメリカ、85234
- Banner MD Anderson Cancer Center
-
Goodyear、Arizona、アメリカ、85338
- Cancer Treatment Centers of America at Western Regional Medical Center
-
-
California
-
Los Angeles、California、アメリカ、90095
- UCLA School of Medicine
-
Palo Alto、California、アメリカ、94305
- Stanford Cancer Institute
-
Redondo Beach、California、アメリカ、90277
- Cancer Care Associates Medical Group, Inc. TORI
-
San Francisco、California、アメリカ、94158
- University of California at San Francisco (PARENT)
-
-
Connecticut
-
Norwich、Connecticut、アメリカ、06360
- Eastern Connecticut Hematology/Oncology Assoc.
-
-
Delaware
-
Newark、Delaware、アメリカ、19713
- Christiana Care Health Services, Inc.
-
-
Florida
-
Boca Raton、Florida、アメリカ、33426
- Sylvester Comprehensive Cancer Center - Deerfield Beach
-
Fort Myers、Florida、アメリカ、33916
- Florida Cancer Specialists (South Region)
-
Hollywood、Florida、アメリカ、33021
- Memorial Healthcare System MRH Cancer Center
-
Orlando、Florida、アメリカ、32806
- Orlando Health, Inc.
-
Tampa、Florida、アメリカ、33139
- Moffitt Cancer Center -Tampa
-
-
Georgia
-
Newnan、Georgia、アメリカ、30263
- Cancer Treatment Centers of America-Georgia
-
-
Illinois
-
Chicago、Illinois、アメリカ、60637
- University of Chicago Medical Center
-
Zion、Illinois、アメリカ、60099
- Cancer Treatment Centers of America
-
-
Kansas
-
Wichita、Kansas、アメリカ、67214
- Cancer Center of Kansas
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70115
- Touro Infirmary
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Detroit、Michigan、アメリカ、48202
- Henry Ford Hospital
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64111
- Saint Luke's Hospital of Kansas City
-
-
New Jersey
-
Livingston、New Jersey、アメリカ、07039
- Saint Barnabas Medical Center
-
-
New York
-
New York、New York、アメリカ、10016
- New York University Medical Center
-
New York、New York、アメリカ、10065
- Memorial Sloan Kettering Hospital
-
New York、New York、アメリカ、10065
- Weill Cornell Medicine Breast Center
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44195
- The Cleveland Clinic Foundation
-
-
Oregon
-
Portland、Oregon、アメリカ、97239
- Oregon Health & Science University
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15212
- Allegheny General Hospital
-
Pittsburgh、Pennsylvania、アメリカ、15219
- University of Pittsburgh Medical Center Health System
-
-
South Carolina
-
Greenville、South Carolina、アメリカ、29601
- St Francis Hospital
-
-
Tennessee
-
Knoxville、Tennessee、アメリカ、37909
- Brig Center for Cancer Care and Survivorship
-
Memphis、Tennessee、アメリカ、38120
- Baptist Cancer Center
-
Nashville、Tennessee、アメリカ、37201
- Tennessee Oncology - Skyline Satellite
-
-
Texas
-
Dallas、Texas、アメリカ、75234
- BloomTrials Clinical Research, LLC
-
Houston、Texas、アメリカ、77030
- The Methodist Hospital Research Institute
-
Houston、Texas、アメリカ、77030
- University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- Virginia Cancer Specialists
-
-
-
-
Cornwall
-
Truro、Cornwall、イギリス、TR1 3LJ
- Royal Cornwall Hospital
-
-
Greater London
-
London、Greater London、イギリス、NW3 2QG
- Royal Free Hospital
-
London、Greater London、イギリス、EC1M 6BQ
- Queen Mary University of London
-
London、Greater London、イギリス、NW1 2PG
- University College London Hospitals
-
-
Lothian Region
-
Edinburgh、Lothian Region、イギリス、EH4 2XU
- Western General Hospital
-
-
Nottinghamshire
-
Nottingham、Nottinghamshire、イギリス、NG5 1PB
- Nottingham University Hospitals City Campus
-
-
Surrey
-
Guildford、Surrey、イギリス、GU2 7XX
- Royal Surrey County Hospital
-
-
-
-
-
Haifa、イスラエル、3109601
- Rambam Health Care Center
-
Jerusalem、イスラエル、9103102
- Shaare Zedek Medical Center
-
Jerusalem、イスラエル、9112001
- Hadassah University Hospital - Ein Kerem
-
Petah Tikva、イスラエル、49100
- Rabin Medical Center-Beilinson Campus
-
Ramat Gan、イスラエル、52363
- Chaim Sheba Medical Center
-
Rehovot、イスラエル、7610001
- Kaplan Medical Center
-
Safed、イスラエル、13100
- Ziv Medical Center
-
Tel Aviv、イスラエル、6423906
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Bologna、イタリア、40138
- Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
-
Brescia、イタリア、25100
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)
-
Catania、イタリア、95125
- Azienda Ospedaliera Univ. Policlinico Gaspare Rodolico
-
Catanzaro、イタリア、88100
- Azienda Ospedaliero Universitaria Mater Domini-Campus Universitario
-
Milan、イタリア、20141
- IEO Istituto Europeo di Oncologia
-
Naples、イタリア、80131
- Istituto Nazionale Tumori Fondazione G. Pascale
-
Rimini、イタリア、47923
- Ospedale degli Infermi
-
Roma、イタリア、00168
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
-
Roma、イタリア、00133
- Azienda Ospedaliera Universitaria Policlinico Tor Vergata
-
-
Lecce
-
Tricase、Lecce、イタリア、73039
- Azienda Ospedaliera Card. G. Panico
-
-
Milano
-
Monza、Milano、イタリア、20900
- Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)
-
Rozzano、Milano、イタリア、20089
- Istituto Clinico Humanitas
-
-
Verona
-
Negrar、Verona、イタリア、37024
- Ospedale Sacro Cuore Don Calabria
-
-
-
-
-
Innsbruck、オーストリア、6020
- Medizinische Universität Innsbruck
-
Linz、オーストリア、4020
- Kepler Universitätsklinikum
-
Salzburg、オーストリア、5020
- LKH - Universitätsklinikum der PMU Salzburg
-
Vienna、オーストリア、1090
- AKH - Medizinische Universität Wien (4305)
-
Wels、オーストリア、4600
- Klinikum Wels-Grieskirchen GmbH
-
-
-
-
Alberta
-
Calgary、Alberta、カナダ、T2N4N2
- Tom Baker Cancer Center
-
-
Ontario
-
Toronto、Ontario、カナダ、M4N 3M5
- Toronto Sunnybrook Hospital
-
-
Quebec
-
Montreal、Quebec、カナダ、H2W 1S6
- McGill University - Dept. Oncology Clinical Research Program
-
-
-
-
-
Athens、ギリシャ、15125
- Athens Medical Center
-
Athens、ギリシャ、11528
- General Hospital of Athens "Alexandra"
-
Athens、ギリシャ、14564
- General Oncology Hospital of Kifissia " Agioi Anargyroi"
-
Heraklion、ギリシャ、71110
- University General Hospital of Heraklion
-
Larissa、ギリシャ、41110
- University General Hospital of Larissa
-
Thessaloniki、ギリシャ、54622
- Bioclinic Thessaloniki
-
Thessaloniki、ギリシャ、54645
- Euromedica General Clinic Thessaloniki
-
Thessaloniki、ギリシャ、56429
- General Hospital Papageorgiou
-
Thessaloniki、ギリシャ、57001
- Interbalkan Hospital of Thessaloniki
-
-
-
-
-
Aarau、スイス、5000
- Hirslanden Medical Center
-
Basel、スイス、4031
- Universitaetsspital Basel
-
Chur、スイス、7000
- Kantonsspital Graubuenden
-
Lausanne、スイス、1011
- Centre Hospitalier Universitaire Vaudois
-
Sankt Gallen、スイス、9007
- Kantonsspital St. Gallen
-
Winterthur、スイス、8401
- Kantonsspital Winterthur
-
Zurich、スイス、8091
- Universitaetsspital Zuerich
-
-
-
-
-
Solna、スウェーデン、17176
- Karolinska universitetssjukhuset - Solna
-
Sundsvall、スウェーデン、85186
- Länssjukhuset Sundsvall-Härnösand
-
Uppsala、スウェーデン、75185
- Akademiska Sjukhuset
-
-
-
-
-
Barcelona、スペイン、08036
- Hospital Clinic de Barcelona
-
Barcelona、スペイン、08035
- Hospital Universitari Vall d'Hebron
-
Barcelona、スペイン、08023
- Hospital Quironsalud Barcelona
-
Barcelona、スペイン、08003
- Hospital del Mar
-
Madrid、スペイン、28034
- Hospital Universitario Ramon y Cajal
-
Madrid、スペイン、28040
- Hospital Universitario Clinico San Carlos
-
Madrid、スペイン、28034
- Hospital Ruber Internacional
-
Madrid、スペイン、28033
- MD Anderson Cancer Centre
-
Málaga、スペイン、29010
- Hospital Clinico Universitario Virgen de la Victoria
-
Seville、スペイン、41009
- Hospital Universitario Virgen Macarena
-
Seville、スペイン、41013
- Hospital Universitario Virgen del Rocio
-
Valencia、スペイン、46014
- Hospital General Universitario de Valencia
-
Valencia、スペイン、46009
- Instituto Valenciano de Oncologia IVO
-
-
Barcelona
-
L'Hospitalet de Llobregat、Barcelona、スペイン、08908
- ICO l'Hospitalet - Hospital Duran i Reynals
-
-
Guipuzcoa
-
San Sebastián、Guipuzcoa、スペイン、20014
- Hospital Universitario Donostia
-
-
La Coruña
-
A Coruña、La Coruña、スペイン、15006
- Complejo Hospitalario Universitario A Coruña
-
-
Tenerife
-
San Cristóbal de La Laguna、Tenerife、スペイン、38320
- Hospital Universitario de Canarias
-
-
Vizcaya
-
Bilbao、Vizcaya、スペイン、48013
- Hospital de Basurto
-
-
-
-
Baden-Wurttemberg
-
Heidelberg、Baden-Wurttemberg、ドイツ、69120
- Universitaetsklinikum Heidelberg
-
-
Bavaria
-
Munich、Bavaria、ドイツ、81377
- Klinikum der Universitaet Muenchen - Campus Grosshardern
-
-
-
-
-
Budapest、ハンガリー、1097
- Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet
-
Budapest、ハンガリー、1122
- Orszagos Onkologiai Intezet
-
Debrecen、ハンガリー、4032
- Debreceni Egyetem
-
Gyula、ハンガリー、5700
- Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza
-
Nyíregyháza、ハンガリー、4400
- SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz
-
Szolnok、ハンガリー、5004
- Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet
-
-
-
-
-
Paris、フランス、75020
- Hopital Tenon
-
Paris、フランス、75005
- Institut Curie - site de Paris
-
-
Bouches-du-Rhône
-
Marseille、Bouches-du-Rhône、フランス、13009
- Institut Paoli Calmettes
-
-
Calvados
-
Caen、Calvados、フランス、14076
- Centre François Baclesse
-
-
Cotes d'Armor
-
Plérin、Cotes d'Armor、フランス、22190
- CARIO - Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie
-
-
Finistere
-
Brest、Finistere、フランス、29609
- CHU Brest - Hôpital Morvan
-
-
Gironde
-
Bordeaux、Gironde、フランス、33076
- Institut Bergonié
-
-
Herault
-
Montpellier、Herault、フランス、34070
- Clinique Clementville
-
Montpellier、Herault、フランス、34298
- Institut Régional du Cancer de Montpellier
-
-
Ille Et Vilaine
-
Rennes、Ille Et Vilaine、フランス、35042
- CRLCC Eugene Marquis
-
-
Loire Atlantique
-
Saint-Herblain、Loire Atlantique、フランス、44805
- ICO - Site René Gauducheau
-
-
Loiret
-
Le Puy-en-Velay、Loiret、フランス、43012
- Centre Hospitalier Emile Roux
-
-
Maine Et Loire
-
Angers、Maine Et Loire、フランス、49055
- ICO - Site Paul Papin
-
-
Nord
-
Valenciennes、Nord、フランス、59322
- Centre Hospitalier Valenciennes
-
-
Paris
-
Paris、Paris、フランス、75475
- Hôpital Saint-Louis - Paris
-
-
Sarthe
-
Le Mans、Sarthe、フランス、72015
- Clinique Victor Hugo - Centre Jean Bernard
-
-
Vaculuse
-
Avignon、Vaculuse、フランス、84918
- Institut Sainte Catherine
-
-
Val De Marne
-
Saint-Mandé、Val De Marne、フランス、94160
- Hôpital d'Instruction des Armees Begin*
-
Villejuif、Val De Marne、フランス、94805
- Institut Gustave Roussy
-
-
-
-
-
Brussels、ベルギー、1000
- Institut Jules Bordet
-
Brussels、ベルギー、1090
- Universitair Ziekenhuis Brussel
-
Brussels、ベルギー、1200
- Cliniques Universitaires Saint-Luc
-
Leuven、ベルギー、3000
- UZ Leuven
-
Loverval、ベルギー、6280
- Grand Hôpital de Charleroi
-
Namur、ベルギー、5000
- CHU UCL Namur
-
Tournai、ベルギー、7500
- Centre Hospitalier Wallonie picarde - Site IMC
-
-
-
-
-
Braga、ポルトガル、4710-243
- Hospital de Braga
-
Guimarães、ポルトガル、4835-044
- Centro Hospitalar do Alto do Ave, EPE
-
Lisbon、ポルトガル、1649-035
- Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria
-
Lisbon、ポルトガル、1400-038
- Fundação Champalimaud
-
Matosinhos Municipality、ポルトガル、4464-509
- Unidade Local de Saúde de Matosinhos, EPE (Hospital Pedro Hispano)
-
Porto、ポルトガル、4200-072
- Instituto Português de Oncologia do Porto Francisco Gentil, EPE
-
Porto、ポルトガル、4099-001
- Centro Hospitalar do Porto, E.P.E. - Hospital de Santo António
-
Santa Maria da Feira、ポルトガル、4520-211
- Centro Hospitalar de Entre o Douro e Vouga, E.P.E - Hospital de São Sebastião
-
Vila Nova de Gaia、ポルトガル、4434-502
- Centro Hospitalar Vila Nova de Gaia/Espinho, E.P.E
-
Vila Real、ポルトガル、5000-508
- Centro Hospitalar de Trás-os-Montes e Alto Douro, EPE
-
-
-
-
-
Moscow、ロシア、115478
- FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin"
-
Moscow、ロシア、143423
- SBIH of Moscow City "Moscow City Oncology Hospital №62" of Moscow Healthcare Departement
-
Yaroslavl、ロシア、150054
- SBIH of Yaroslavl Region "Regional Clinical Oncological Hospital"
-
-
-
-
Anhui
-
Hefei、Anhui、中国、230001
- Anhui Provincial Hospital
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100853
- Chinese PLA General Hospital
-
Beijing、Beijing Municipality、中国、100021
- Cancer Hospital Chinese Academy of Medical Sciences
-
-
Fujian
-
Fuzhou、Fujian、中国、350025
- Fuzhou General Hospital of Nanjing Military Area Command of Chinese PLA
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510120
- Sun Yat-sen Memorial hospital, Sun Yat-sen University
-
-
Heilongjiang
-
Harbin、Heilongjiang、中国、150081
- Harbin Medical University Cancer Hospital
-
-
Hubei
-
Wuhan、Hubei、中国、430079
- Hubei Cancer Hospital
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210008
- The Affiliated Drum Tower Hospital of Nanjing University
-
-
Jilin
-
Changchun、Jilin、中国、130000
- The First Hospital of Jilin University
-
Changchun、Jilin、中国、130012
- Jilin Cancer Hospital
-
-
Liaoning
-
Shenyang、Liaoning、中国、110042
- Liaoning Cancer Hospital & Institute
-
-
Ningxia Hui
-
Yinchuan、Ningxia Hui、中国、750004
- General Hospital of Ningxia Medical University
-
-
Shandong
-
Linyi、Shandong、中国、276001
- Linyi Cancer Hospital
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200080
- Shanghai General Hospital
-
Shanghai、Shanghai Municipality、中国、20032
- Fudan University Shanghai Cancer Center
-
-
Sichuan
-
Chengdu、Sichuan、中国、610041
- West China Hospital, Sichuan University
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310022
- Zhejiang Cancer Hospital
-
Hangzhou、Zhejiang、中国、310016
- Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
-
-
-
-
-
Kaohsiung City、台湾、807
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Tainan、台湾、704
- National Cheng Kung University Hospital
-
Taipei、台湾、100
- National Taiwan University Hospital
-
-
-
-
Aichi-ken
-
Nagoya、Aichi-ken、日本、464-8681
- Aichi Cancer Center Hospital
-
-
Chiba
-
Kashiwa-shi、Chiba、日本、277-8577
- National Cancer Center Hospital East
-
-
Ehime
-
Matsuyama、Ehime、日本、791-0280
- NHO Shikoku Cancer Center
-
-
Fukuoka
-
Fukuoka、Fukuoka、日本、811-1395
- NHO Kyushu Cancer Center
-
-
Fukushima
-
Fukushima、Fukushima、日本、960-1295
- Fukushima Medical University Hospital
-
-
Hiroshima
-
Hiroshima、Hiroshima、日本、730-8518
- Hiroshima City Hiroshima Citizens Hospital
-
-
Hokkaido
-
Sapporo、Hokkaido、日本、003-0804
- NHO Hokkaido Cancer Center
-
-
Hyōgo
-
Nishinomiya-shi、Hyōgo、日本、663-8501
- Hyogo College of Medicine Hospital
-
-
Kagoshima-ken
-
Kagoshima、Kagoshima-ken、日本、892-0833
- Hakuaikai Sagara Hospital
-
-
Kanagawa
-
Isehara、Kanagawa、日本、259-1193
- Tokai University Hospital
-
Yokohama、Kanagawa、日本、241-8515
- Kanagawa Cancer Center
-
-
Osaka
-
Osaka、Osaka、日本、540-0006
- NHO Osaka National Hospital
-
-
Osakasayama-shi
-
Onohigashi、Osakasayama-shi、日本、589-8511
- Kindai University Hospital
-
-
Saitama
-
Kitaadachi-gun、Saitama、日本、362-0806
- Saitama Cancer Center
-
-
Shizuoka
-
Sunto-gun、Shizuoka、日本、411-8777
- Shizuoka Cancer Center
-
-
Tokyo-To
-
Kōtoku、Tokyo-To、日本、135-8550
- Cancer Institute Hospital of JFCR
-
Minatoku、Tokyo-To、日本、105-8470
- Toranomon Hospital
-
Shinagawa-Ku、Tokyo-To、日本、142-8666
- Showa University Hospital
-
-
-
-
-
Daegu、韓国、41404
- Kyungpook National University Chilgok Hospital
-
Seoul、韓国、03080
- Seoul National University Hospital
-
Seoul、韓国、05505
- Asan Medical Center
-
Seoul、韓国、06351
- Samsung Medical Center
-
Seoul、韓国、06591
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
Seoul、韓国、120-752
- Severance Hospital, Yonsei University Health System
-
-
Gyeonggi-do
-
Goyang-si、Gyeonggi-do、韓国、10408
- National Cancer Center
-
Incheon、Gyeonggi-do、韓国、22332
- Inha University Hospital
-
Seongnam-si、Gyeonggi-do、韓国、13620
- Seoul National University Bundang Hospital
-
Suwon、Gyeonggi-do、韓国、16499
- Ajou University Hospital
-
-
North Chungcheong
-
Cheongju-si、North Chungcheong、韓国、361-711
- Chungbuk National University Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Is the age of majority in their country
-
Has pathologically documented breast cancer that:
- Is unresectable or metastatic
- Has low-HER2 expression defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested)
- Is HR-positive or HR-negative
- Has progressed on, and would no longer benefit from, endocrine therapy
- Has been treated with 1 to 2 prior lines of chemotherapy/adjuvant in the recurrent or metastatic setting
- Was never previously HER2-positive (ICH 3+ or ISH+) on prior pathology testing (per American Society of Clinical Oncology-College of American Pathologists [ASCO-CAP] guidelines)
-
Has documented radiologic progression (during or after most recent treatment)
-
Has adequate archival tumor samples available or is wiling to provide fresh biopsies prior to randomization for:
- assessment of HER2 status
- assessment of post-treatment status
-
Has at least 1 measurable lesion per Response Evaluation Criteria In Solid Tumors 1.1
-
Has protocol-defined adequate cardiac, bone marrow, renal, hepatic and blood clotting functions
-
Male and female participants of reproductive/childbearing potential, agrees to follow instructions for method(s) of contraception and agrees to avoid preserving ova or sperm for at least 4.5 months after treatment (or longer, per locally approved labels)
Exclusion Criteria:
- Is ineligible for all options in the physician's choice arm
- Has breast cancer ever assessed with high-HER2 expression
- Has previously been treated with any anti-HER2 therapy, including an antibody drug conjugate
- Has uncontrolled or significant cardiovascular disease
- Has spinal cord compression or clinically active central nervous system metastases
- Has history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
- Has any medical history or condition that per protocol or in the opinion of the investigator is inappropriate for the study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Trastuzumab deruxtecan
HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to DS8201a |
DS-8201a is a lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously
他の名前:
|
|
アクティブコンパレータ:Physician's Choice
HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to Physician's choice from the following options:
|
Administered according to label, as one option for Physician's Choice (determined before randomization) Administered according to label, as one option for Physician's Choice (determined before randomization) Administered according to label, as one option for Physician's Choice (determined before randomization) Administered according to label, as one option for Physician's Choice (determined before randomization) Administered according to label, as one option for Physician's Choice (determined before randomization) |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
時間枠:From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
全体的な生存事象(死亡)の数
時間枠:無作為化の日から何らかの原因による死亡日まで、最長約 3 年間
|
無作為化の日から何らかの原因による死亡日まで、最長約 3 年間
|
|
|
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-low Breast Cancer (All Patients) Regardless of Hormone Receptor Status
時間枠:From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
|
Progression-free Survival Based on Investigator Assessment in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
時間枠:From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
|
Progression-free Survival Based on Investigator Assessment in Participants With HER2-low Breast Cancer (All Patients)
時間枠:From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
|
|
Overall Survival (OS) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
時間枠:From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive. |
From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
|
Overall Survival (OS) in All Patients
時間枠:From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive. |
From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
|
Best Overall Response and Confirmed Objective Response Rate (ORR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
時間枠:From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
|
Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment. |
From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
|
|
Best Overall Response and Confirmed Objective Response Rate (ORR) in Participants With HER2-low Breast Cancer (All Patients)
時間枠:From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
|
Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment. |
From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
|
|
Duration of Response in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
時間枠:From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
|
Duration of Response (DoR) is defined as the date of the first documented objective response (complete response [CR] or partial response [PR]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
|
|
Duration of Response in Participants With HER2-low Breast Cancer (All Patients)
時間枠:From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
|
Duration of Response (DoR) is defined as the date of the first documented objective response (complete response [CR] or partial response [PR]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method. |
From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
All-Cause Mortality
時間枠:From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
All-cause mortality is defined as all anticipated and unanticipated deaths due to any cause, with the number and frequency of such events by arm or comparison group of the clinical study. |
From the date of randomization up to the date of death due to any cause, up to approximately 3 years
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Global Clinical Leader、Daiichi Sankyo
出版物と役立つリンク
一般刊行物
- Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5.
- Jhaveri K, Eli LD, Wildiers H, Hurvitz SA, Guerrero-Zotano A, Unni N, Brufsky A, Park H, Waisman J, Yang ES, Spanggaard I, Reid S, Burkard ME, Vinayak S, Prat A, Arnedos M, Bidard FC, Loi S, Crown J, Bhave M, Piha-Paul SA, Suga JM, Chia S, Saura C, Garcia-Saenz JA, Gambardella V, de Miguel MJ, Gal-Yam EN, Rapael A, Stemmer SM, Ma C, Hanker AB, Ye D, Goldman JW, Bose R, Peterson L, Bell JSK, Frazier A, DiPrimeo D, Wong A, Arteaga CL, Solit DB. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol. 2023 Oct;34(10):885-898. doi: 10.1016/j.annonc.2023.08.003. Epub 2023 Aug 18.
- Ueno NT, Cottone F, Dunton K, Jacot W, Yamashita T, Sohn J, Tokunaga E, Prat A, Tsurutani J, Park YH, Rugo HS, Xu B, Cardoso F, Mitri Z, Mahtani R, Aguilar CO, Xiao F, Harbeck N, Cameron DA, Modi S. Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC. Oncologist. 2025 May 8;30(5):oyaf048. doi: 10.1093/oncolo/oyaf048.
- Yamashita T, Sohn JH, Tokunaga E, Niikura N, Park YH, Lee KS, Chae YS, Xu B, Wang X, Im SA, Li W, Lu YS, Aguilar CO, Nishijima S, Nishiyama Y, Sugihara M, Modi S, Tsurutani J. Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study. Breast Cancer. 2024 Sep;31(5):858-868. doi: 10.1007/s12282-024-01600-7. Epub 2024 Jun 17.
- Ma R, Shi Y, Yan R, Yin S, Bu H, Huang J. Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low/positive advanced breast cancer:A meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol. 2024 Apr;196:104305. doi: 10.1016/j.critrevonc.2024.104305. Epub 2024 Mar 3.
- Rugo HS, Crossno CL, Gesthalter YB, Kelley K, Moore HB, Rimawi MF, Westbrook KE, Buys SS. Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer. JCO Oncol Pract. 2023 Aug;19(8):539-546. doi: 10.1200/OP.22.00480. Epub 2023 May 19.
- Narayan P, Dilawari A, Osgood C, Feng Z, Bloomquist E, Pierce WF, Jafri S, Kalavar S, Kondratovich M, Jha P, Ghosh S, Tang S, Pazdur R, Beaver JA, Amiri-Kordestani L. US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer. J Clin Oncol. 2023 Apr 10;41(11):2108-2116. doi: 10.1200/JCO.22.02447. Epub 2023 Feb 13.
- Iyengar AR, Downs EP, Mehta S, Rangarajan N, Woo MS, Sredni ST, Donato RD, Simsek S, Wilson DM, Krieser K, Patzke EB, Kyek N, Anderson C, Wagner T, Hipp J, Nassar A, Barman H. HER2-Ultralow: Prevalence, Characteristics, and Treatment Choices Among Advanced Breast Cancer Patients With Tumors Initially Scored as IHC 0. Breast J. 2026;2026(1):e7212120. doi: 10.1155/tbj/7212120.
- Modi S, Jacot W, Iwata H, Park YH, Vidal Losada M, Li W, Tsurutani J, Ueno NT, Zaman K, Prat A, Papazisis K, Rugo HS, Yamashita T, Harbeck N, Im SA, De Laurentiis M, Pierga JY, Wang X, Gombos A, Tokunaga E, Orbegoso Aguilar C, Yung L, Xiao F, Cheng Y, Cameron D. Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial. Nat Med. 2025 Dec;31(12):4205-4213. doi: 10.1038/s41591-025-03981-4. Epub 2025 Oct 8.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 病理学的プロセス
- 部位別新生物
- 新生物
- 腫瘍性プロセス
- 皮膚疾患
- 乳房の病気
- 病理学的状態、徴候および症状
- 皮膚および結合組織疾患
- 乳房腫瘍
- 新生物転移
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 核酸、ヌクレオチド、およびヌクレオシド
- 炭化水素
- シクロパラフィン
- 炭化水素、環状
- 炭化水素、周期的
- テルペン
- タキソイド
- シクロデカン
- Diterpenes
- デオキシシチジン
- シチジン
- ピリミジンヌクレオシド
- ピリミジン
- ヌクレオシド
- ウラシル
- ピリミジノン
- デオキシリボヌクレオシド
- フルオロウラシル
- カペシタビン
- ゲムシタビン
- パクリタキセル
- 130 nmアルブミンに縛られたパクリタキセル
- トラスツズマブderuxtecan
- エリブリン
その他の研究ID番号
- DS8201-A-U303
- 2018 (米国 NIH グラント/契約)
- 2018-003069-33 (EudraCT番号)
- 184223 (レジストリ識別子:JAPIC CTI)
- DESTINY-B04 (その他の識別子:Daiichi Sankyo and AstraZeneca)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD 共有時間枠
Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD 共有アクセス基準
Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。